We also observed higher number of mutational hotspots in 3 actionable genes in KRAS (1164 versus 219, p < 0.0001, q-0.0005), EGFR (814 versus 103, p < 0.0001, q-0.0005) and TP53 (1195 versus 499, p < 0.0001, q-0.0005) in GENIE than in TCGA in NSCLC cases. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.